- Home
- NYC vs NERV Comparison
NYC vs NERV Comparison
Compare NYC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | NERV |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 29.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NYC | NERV |
|---|---|---|
| Price | $9.01 | $4.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.2K | ★ 55.2K |
| Earning Date | 11-19-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,688,000.00 | N/A |
| Revenue This Year | $8.40 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.03 | $1.15 |
| 52 Week High | $16.30 | $12.46 |
Technical Indicators
Market Signals| Indicator | NYC | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 57.09 |
| Support Level | $8.12 | $3.82 |
| Resistance Level | $8.78 | $4.86 |
| Average True Range (ATR) | 0.47 | 0.28 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 81.99 | 55.77 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.